Nephera is a medical device company developing the RenaSense, a novel electrical stimulation device for the urinary system, aimed to improve and maintain kidney functionality in patients suffering from advanced heart failure, when hospitalized. Reduced kidney function in these patients is known to be associated with disease progression, higher hospital readmission rates and increased mortality. Heart Failure is a key health issue that affects 6 million Americans and more than 22 million individuals worldwide. Treating heart failure costs an estimated $40 billion per year in the U.S. (with over one million hospitalizations) and nearly $80 billion worldwide in direct medical care.
CEO: Gill Bar-Yoseph
Evergreen Partner: Ronit Bendori